Openbookopenbook
Equity
Affymax Inc.(AFFY)
USD --+0.00%
Reward38Moderate
Risk78High
📊75%Data
Strong 7300% profit margin · Revenue down 92% YoY
AFFY
+0.0 · +0.00%
USD · PINK
Affymax Inc. | Healthcare
Earnings Deterioration
Market Cap:41239
ℹ️
Reward Rating
38
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
78
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on AFFY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $1.00.

What is Affymax Inc.?

Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States.

AFFY · Verdict

Limited reward · high risk

AFFY has limited near-term tailwinds — volatility and cash flow weigh on the model output.

Based on 88% data coverage

AFFY · Verdict

What’s working & what to watch

Watchouts 5

  • Volatility5/100

    Weak vs peers

  • Cash flow12/100

    -4919% free-cash-flow margin

  • Growth25/100

    Rev -77.0% CAGR · earnings +0.8%

  • Profitability41/100

    -1054% net margin · 112% ROE

  • Balance sheet44/100

    Current ratio 0.71

Model-based scoring. For information only — not financial advice.

What is Affymax Inc.?

Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 41.24K.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap41.24K
P/E RatioN/A
Dividend YieldN/A
52 Week High0.003
52 Week Low0.0001
Last AnnualDecember
IPO Date12/15/2006
IncorporatedUSA
Shares Outstanding37M
No. of Employees2
IndustryBiotechnology
ExchangePINK
Beta8.123
CurrencyUSD
Websitewww.affymax.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.